AssetMark Inc
TARS icon

AssetMark Inc’s Tarsus Pharmaceuticals TARS Stock Holding History

AssetMark Inc’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$881 Hold
14
– – ﹤0.01% 3173
2026
Q1 		$982 Hold
14
– – ﹤0.01% 3038
2025
Q4 		$1.15K Hold
14
– – ﹤0.01% 2902
2025
Q3 		$832 Hold
14
– – ﹤0.01% 2824
2025
Q2 		$567 Buy
+14
New +$630 ﹤0.01% 2722

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AssetMark Inc's TARS Position: Q2 2026 in Review

AssetMark Inc held its Tarsus Pharmaceuticals (TARS) position steady in Q2 2026 at 14 shares worth $881. The position accounts for ﹤0.01% of the portfolio, ranked #3173.

AssetMark Inc first reported a position in TARS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.15K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • AssetMark Inc held 14 shares of Tarsus Pharmaceuticals worth $881 as of Q2 2026.
  • AssetMark Inc left its Tarsus Pharmaceuticals share count unchanged in Q2 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #3173 holding.
  • AssetMark Inc first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • AssetMark Inc's Tarsus Pharmaceuticals position peaked at $1.15K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.